1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017

DelveInsight’s, “PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017”, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors.

This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also assesses the PD-1 and PD-L1 Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

Scope
- The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors
- The report provides the marketed drugs information including its sales, development activities and details of patent expiry
- The report provides the insight of current and future market for PD and PD-L1 inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the PD-1 and PD-L1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for PD-1 and PD-L1 Inhibitors and also provide company profiling
- The report also gives the information of dormant pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy
- Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Complete MOA intelligence and complete understanding over therapeutics development for PD-1 and PD-L1 Inhibitors
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding PD-1 and PD-L1 Inhibitors pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017
Introduction
Executive Summary
Programmed Death 1 (PD-1)
Programmed Death Ligand 1 (PD-L1)
Role of PD-1 and PD-L1 pathways
MOA of PD-1 and PD-L1 inhibitors
Significance of PD-1 and PD-L1 inhibitors
PD-1 and PD-L1 Active Therapy Areas and Epidemiology
Metastatic Renal Cell Carcinoma
Squamous Cell Carcinomas of the Head and Neck
Metastatic Colorectal Cancer
Non-Small Cell lung cancer
Biomarkers - PD-1 and PD-L1 inhibitors
Market Overview
Comparative Analysis of Pipeline andMarketed Drugs
Marketed Product of PD-1 and PD-L1 drugs -Overview
Marketed Drug Candidate Profiles
Pembrolizumab
Nivolumab
Atezolizumab
Marketed Drugs Sales
Details of Patent Expiry of Marketed Drugs
Current and Future Market for PD and PD-L1 inhibitors
Challenges and Barriers associated with use of PD and PD-L1 inhibitors
PD-1/PD-L1Combinations Creating Boom
Pipeline Therapeutics
An overview of pipeline products
Pipeline Therapeutics Overview
Therapeutics under Development by MOA
Therapeutics under Development by Companies
Last Stage Products (Phase III and Filed)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-Clinical and Discovery Products
Comparative Analysis
Unknown Stages Molecules
Therapeutic Assessment of pipeline
Therapeutics under Development by Product Type
Therapeutics under Development by Phase for Monotherapy
Therapeutics under Development by Phase for Combination therapy
Therapeutics under Development by Molecule Type
Assessment by Stage and Molecule Type
Therapeutics under Development by Route of Administration
Assessment by Stage and Route of Administration
Dormant Products
Comparative Analysis
SWOT Analysis
Appendix
Methodology
Consulting Services
About DelveInsight
Contact Us
Disclaimer


List of Tables
Table 1: Marketed and Pipeline drugs forPD-1 and PD-L1 Drugs, 2017
Table 2: PD-1 Marketed Drugs, 2017
Table 3: Sales of Marketed drugs, 2017
Table 4: Details of patent expiry of marketed molecules, 2017
Table 5: Merck's drug- Keytruda (Pembrolizumab) Partners for Combination Therapies
Table 6:Bristol Myers Squibb's drug-Opdivo (nivolumab) Partners for Combination Therapies
Table 7: Roche's drug-Atezolizumab (MPDL-3280A) Partners for Combination Therapies
Table 8: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2017
Table 9: ComparativeTable forPD-1 and PD-L1 inhibitors Drugs, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Last Stage Products (Phase III and Filed),2017
Table 12: Mid Stage Products (Phase II), 2017
Table 13: Early Stage Products (Phase I and IND), 2017
Table 14: Pre-Clinical and Discovery Products, 2017
Table 15: Number of Products by Product Type for PD-1 and PD-L1 Inhibitors, 2017
Table 16: Number of Monotherapy Products for PD-1 and PD-L1 inhibitors, 2017
Table 17:Number of Combination therapy Products forPD-1 and PD-L1 inhibitors, 2017
Table 18: Number of Products under Development by Molecule Type, 2017
Table 19: Assessment by Stage and Molecule Type, 2017
Table 20:Number of Products under Development by Route of Administration, 2017
Table 21:Assessment by Stage and Route Of Administration, 2017
Table 22: Dormant Products, 2017


List of Figures
Figure 1:Marketed and Pipeline drugs forPD-1 and PD-L1 Drugs, 2017
Figure 2: Sales of marketed drugs, 2017
Figure 3: Details of patent expiry of marketed molecules, 2017
Figure 4: Number of Products under Development forPD-1 and PD-L1 inhibitors Drugs, 2017
Figure 5: Comparative Graph forPD-1 and PD-L1 inhibitors Drugs, 2017
Figure 6:Last Stage Products (Phase III), 2017
Figure 7: Mid Stage Products (Phase II), 2017
Figure 8: Early Stage Products (Phase I and IND), 2017
Figure 9:Pre-Clinical and Discovery Products, 2017
Figure 10: Number of Products by Product Type forPD-1 and PD-L1 Inhibitors, 2017
Figure 11: Number of Monotherapy Products forPD-1 and PD-L1 inhibitors, 2017
Figure 12: Number of Combination therapy Products forPD-1 and PD-L1 inhibitors, 2017
Figure 13: Percentage of pipeline drugs by Molecule Type (%), 2017
Figure 14: Assessment by Stage and Molecule Type, 2017
Figure 15:Percentage of pipeline drugs by Route of Administration(%), 2017
Figure 16: Assessment by Stage and Route of Administration, 2017
Figure 17: Dormant Products, 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

  • $ 75000
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both ...

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...


Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in the US

  • February 2017
    9 pages
  • Anti-Infective  

    Influenza  

  • United States  

View report >

Therapy Market in Sweden

  • February 2017
    8 pages
  • Therapy  

    Hormone  

    Antidiabetics  

  • Sweden  

View report >

Contraceptive Market in the Netherlands

  • February 2017
    8 pages
  • Contraceptive  

  • Netherlands  

View report >

Diabetes Statistics

5 days ago

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.